Clinical Trial Update: SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS [Phase 1]

View source ↗

Summary

Phase 1 trial SENTI-202 evaluating off-the-shelf logic-gated CAR NK cells for CD33 and/or FLT3-expressing hematologic cancers including acute myeloid leukemia a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• SENTI-202 CAR NK cell therapy (CAR NK cell therapy targeting CD33 and FLT3)

Snippet

Sponsor: Senti Biosciences | Conditions: AML/MDS, CD33 Expressing Hematological Malignancies | Phase 1 | Status: ACTIVE_NOT_RECRUITING